Algeta ASA : Algeta ASA : Proposal from the Nomination Committee to the Annual General Meeting on 11 April 2013 To the Shareholders of Algeta ASA Reference is made to the announcement of 19 March 2013 regarding Algeta ASA's Annual General Meeting 2013 and agenda item 13: Election of members to the Board of Directors. At the time of the announcement, the Nomination Committee had not decided on its proposal for new members of the Board of Directors. The Nomination Committee has now made its decision - please find the proposal attached. ### For further information, please contact: Mike Booth / Renate Birkeli +47 23 00 67 32 Communications & Corporate Affairs firstname.lastname@example.org Media enquiries: Mark Swallow +44 207 638 9571 Citigate Dewe Rogerson email@example.com Knut Ekern +47 22 04 82 00 Gambit Hill & Knowlton firstname.lastname@example.org US investor enquiries: Tricia Swanson +1 646 378 2953 The Trout Group email@example.com About Algeta Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com. Forward-looking Statements This news release contains certain forward-looking statements that are based on uncertainty, as they relate to events and depend on circumstances that will occur in the future and which, by their nature, may have an impact on results of operations and the financial condition of Algeta. Such forward-looking statements reflect our current views and are based on the information currently available to Algeta. Algeta cannot give any assurance as to whether such forward looking statements will prove to be correct. These forward looking statements include statements regarding interactions with regulatory authorities, our anticipated co-promotion of radium-223 in the US, additional clinical development of radium-223 and our TTC program. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the success of future clinical trials, collaborations with other companies in the development of targeting molecules, the ability to identify and hire a sufficient number of qualified employees for the US field force, growth management, general economic and business conditions and the pricing environment, the impact of competition, the ability to successfully commercialize radium-223 and our other products, the risk that costs associated with the co-promotion of radium-223 may be greater than anticipated, the risk that research & development will not yield new products that achieve commercial success, manufacturing capacity, the risk of non-approval of patents not yet granted, risks in obtaining regulatory approvals for radium-223 and our other products and difficulties of obtaining relevant governmental approvals for new products, and the other risks and uncertainties described in our annual report. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Proposal from the Nomination Committee to the AGM 2013 ------------------------------------------------------------------------------ This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Algeta ASA via Thomson Reuters ONE HUG#1690509
Algeta ASA : Algeta ASA : Proposal from the Nomination Committee to the Annual General Meeting on 11 April 2013
Press spacebar to pause and continue. Press esc to stop.